AFP and hepatocellular carcinoma: Among DAA-treated patients, the univariate analysis identified the following risk factors for HCC-R: an interval period between curative treatment for HCC and initiation of the DAA treatment (p = 0.0288), total number of treatments (p = 0.0058), palliative treatment prior to DAA treatment (p = 0.0288), total bilirubin at SVR12 (p = 0.0157), AFP at SVR12 (p = 0.0028), total cholesterol at SVR12 (p = 0.0134), and ALBI score at SVR12 (p = 0.0258) (Table 2).